Division of Infectious Diseases

Division of Infectious DiseasesDepartment of Medicine

Division of Infectious DiseasesDepartment of Medicine

Gary Simon David Parenti Carmen Tuazon Afsoon Roberts Angelike Liappis

Fred Gordin Virginia Kan Cynthia Gibert Debra Benator Anne Labriola

Division of Infectious Diseases

HIV/AIDS Clinical Services

• GWU Hospital • 371 beds• 15,000

admissions/yr

• VAMC Hospital• 120 beds

• Medical Faculty Associates (MFA)– Ambulatory Care

Building (ACC)• 280 physicians• 41 medical

specialties • 1,500 patients/day

Division of Infectious Diseases

HIV/AIDS Clinical ServicesHIV/AIDS Clinical Services• Infectious Diseases Clinic

• Outpatient management of antiretroviral therapy (ARVT)

• Treatment of naïve and ARVT experienced 800 HIV/AIDS patients at GWU

» 30% women» 50% African American» 15% Hepatitis C co-infection» 12% Hepatitis B co-infection

– 800 HIV/AIDS patients at the VAMC

• Opportunistic infection therapy/prevention

• Infectious Diseases Clinic • Outpatient management of antiretroviral therapy

(ARVT)• Treatment of naïve and ARVT experienced 800

HIV/AIDS patients at GWU» 30% women» 50% African American» 15% Hepatitis C co-infection» 12% Hepatitis B co-infection

– 800 HIV/AIDS patients at the VAMC

• Opportunistic infection therapy/prevention

Division of Infectious Diseases

HIV/AIDS Clinical ServicesGWU/MFA

Clinical Trials Unit (CTU)• Three FT study coordinators

– Suzanne Schuck, RN MPH– Nicole Bisby– Aimee Desrosiers, PAC MPH

• Phlebotomy lab, two – 80˚C freezers, adjacent to clinic

• Investigator-initiated projects and Phase I-IV clinical trials

ID Research Laboratory• Ross 705• Bona Yoon, research associate • Translational projects

VAMCClinical Trials Unit

(CPCRA)

VA Research Laboratory• Clinical applications and

translational research projects

– Flow cytometry/CD4– HIV quantitation by

bDNA assay– HIV genotypic

resistance testing– HCV quantitation– HCV genotyping by

real-time PCR

Division of Infectious Diseases

HIV/AIDS Clinical ServicesHIV/AIDS Clinical Services• Infectious Diseases Clinic

• Active HIV/AIDS research initiatives – Studies involving: new drugs/drug classes, vaccines, immunomodulating

therapies– Pro-atherogenic potential of antiretroviral drugs (R01 HL65955) – Immune reconstitution mediated events, opportunistic infection

• Propose new bedside-to-bench initiatives: host and viral factors affecting viral load and the response to therapy

• New programs being developed– Application October, 2006 Ryan White funding– Expanding the treatment of infectious hepatitis

• Infectious Diseases Clinic• Active HIV/AIDS research initiatives

– Studies involving: new drugs/drug classes, vaccines, immunomodulating therapies

– Pro-atherogenic potential of antiretroviral drugs (R01 HL65955) – Immune reconstitution mediated events, opportunistic infection

• Propose new bedside-to-bench initiatives: host and viral factors affecting viral load and the response to therapy

• New programs being developed– Application October, 2006 Ryan White funding– Expanding the treatment of infectious hepatitis

Division of Infectious Diseases

HIV/AIDS Clinical ServicesHIV/AIDS Clinical Services• ID Hospital consultation service

• ~ 100 consultations/month– ~ 50% of consults for HIV/AIDS, all services– Majority are for the management of complications

of untreated or undiagnosed HIV/AIDS

• New programs being developed – Determining barriers to healthcare access for

hospitalized patients with end-stage HIV/AIDS– Predictors of non-compliance with clinical follow-

up after hospitalization

• ID Hospital consultation service • ~ 100 consultations/month

– ~ 50% of consults for HIV/AIDS, all services– Majority are for the management of complications

of untreated or undiagnosed HIV/AIDS

• New programs being developed – Determining barriers to healthcare access for

hospitalized patients with end-stage HIV/AIDS– Predictors of non-compliance with clinical follow-

up after hospitalization